Price
$195.00+22.77%Social Signal Score
Analyst Ratings
29 analysts52-week range
- Last close
- $195.00
- Off 52w high
- -27.5%
- 200-day average
- $100.42
- vs 200-day
- +94.2%
Revenue
$1.31B+3575.40%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Stéphane Bancel
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 4,700
- Beta
- 0.90
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- 7.68
Financials
Revenue
$1.31B+3575.4%Net Income
$162.00MEBITDA
$239.00MFree Cash Flow
$-1.61BEPS (diluted)
$0.38Shares Outstanding (diluted)
430.00M+570.9%Operating Expenses
$865.00MCash & Debt
$5.17BReturn of Capital
$0.00Revenue by Segment (annual)
$1.94BQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.94B | $-2.82B | $-7.26 |
| 2024 | $3.20B | $-3.56B | $-9.27 |
| 2023 | $6.85B | $-4.71B | $-12.34 |
| 2022 | $18.88B | $8.36B | $21.26 |
| 2021 | $17.74B | $12.20B | $30.31 |
| 2020 | $803.39M | $-747.06M | $-1.96 |
| 2019 | $60.21M | $-514.02M | $-1.55 |
| 2018 | $135.07M | $-384.73M | $-1.17 |
| 2017 | $205.82M | $-255.92M | $-0.72 |
| 2016 | $108.40M | $-216.21M | $-3.79 |
Valuation
MRNAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70-28.36%Social Signal Score
Mentions (100)
- News (RSS)fool·2d ago·Positive
Moderna vs. BioNTech: Why Only 1 Is a Buy Heading Into 2027 One of these mRNA pioneers has the products and pipeline to drive growth.
View source ↗ - 4chan /biz/biz·3d ago·Positive
Why are these fools still trying to pump Moderna with misleading headlines? Sad. Where's 'to $300' anon?
View source ↗ - 4chan /biz/biz·3d ago·Positive
>When the bull is long MRNA
View source ↗ - 4chan /biz/biz·3d ago·Neutral
MRNA already sub 200 again
View source ↗ - Newszacks.com·3d ago·Neutral
Moderna: Can the Vaccine Business Fund Its Next Phase of Growth? MRNA's ambitious oncology investments and expanding vaccine portfolio drive growth, but rising costs and uncertain revenues test its financial recovery.
View source ↗ - Newsfool.com·3d ago·Negative
Moderna's Cancer Vaccine Worked -- and the Stock Plunged Anyway. Here's What Investors Are Missing. Moderna's personalized melanoma vaccine, paired with Merck's Keytruda, cut the risk of recurrence or death by 42% in a Phase 3 trial. Analysts warmed to Moderna's vaccine after the full data showed a 58% lower risk of recurrence or death after six months.
View source ↗ - Newsseekingalpha.com·4d ago·Positive
Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript Moderna, Inc. (MRNA) Presents at Jefferies Global Healthcare Conference 2026 Transcript
View source ↗ - Newsmarketbeat.com·4d ago·Neutral
Moderna Targets Year-End Cancer Therapy Filing, Sees Multibillion-Dollar Opportunity Moderna NASDAQ: MRNA is preparing to file a U.S. application for its individualized cancer therapy intismeran by year-end, as executives outlined manufacturing plans and upcoming trial results following positive phase III melanoma data.
View source ↗ - 4chan /biz/biz·5d ago·Negative
>>62920108 This guy still has an audience after getting exposed for rugging s******** left and right for $50? Pretty sure this was after the MRNA mania where he probably blew up
View source ↗ - Newsfool.com·6d ago·Neutral
Is Moderna's Cancer Vaccine a Game Changer for the Stock? Intismeran and Keytruda have demonstrated in clinical trials that they can drastically improve outcomes for melanoma patients. The combined treatment has reduced the risk of death and melanoma spreading or returning.
View source ↗ - News (RSS)fool·8d ago·Negative
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027? Axsome's revenue has climbed about 54% while Moderna's net losses run deep, but a steep valuation gap may tip the scales for patient investors.
View source ↗ - Newsfool.com·8d ago·Negative
Axsome Therapeutics vs. Moderna: Which Biotech Innovator Stock Is a Better Buy for 2027? Axsome Therapeutics is experiencing rapid revenue growth driven by its portfolio of central nervous system treatments. Moderna is diversifying its messenger RNA platform into respiratory vaccines and oncology while facing significant net losses.
View source ↗ - News (RSS)seekingalpha·9d ago·Neutral
Moderna, Inc. (MRNA) Analyst/Investor Day - Slideshow
View source ↗ - Newszacks.com·9d ago·Neutral
Moderna Issues Cost Outlook Amid Revenue Uncertainty, Stock Falls MRNA shares fall as 2027 cost projections raise concerns, while limited visibility into future revenue growth weighs on investor sentiment.
View source ↗ - News (RSS)wsj·10d ago·Neutral
Health Care Roundup: Market Talk Find insight on Moderna, Merck KGaA and more in the latest Market Talks covering the health care sector.
View source ↗ - 4chan /biz/biz·10d ago·Neutral
>>62894013 I got told this by 3 people on /smg/ when I bought MRNA during hanta virus.
View source ↗ - News (RSS)marketwatch·10d ago·Negative
The world’s most sophisticated drug companies are putting billions into vaccines — despite the political environment Look at the promising data for Moderna and Merck’s experimental cancer vaccine and the research suggesting the shingles vaccine can delay dementia.
View source ↗ - News (RSS)ft·12d ago·Negative
Moderna chasing ‘holy grail’ of cancer prevention Chief executive Stéphane Bancel says cancer vaccine could be bigger than best-selling oncology drug
View source ↗ - 4chan /biz/biz·12d ago·Negative
…atch for a random whatever startup to start a drug trial and hope they either get approved or expedited in their drug trial, it'll be interpreted as approval mostly. Moderna pumped 250% because people stupidly thought they cured cancer. Ino? It initially pumped on the misunderstood expedition case, but suddenly pumped again today 25% after nearly fully correcting on no further news. These are high-risk, though, since they could just be 100% rejected for just submitting a petri dish with c*m.
View source ↗ - 4chan /biz/biz·13d ago·Positive
MRNA doesnt f****** care. Already more than halfway to 300. I remember when people where telling me i was insane to buy at 135.
View source ↗ - Newsfool.com·13d ago·Positive
Moderna's Q3 Numbers May Have Seemed Impressive, but They Aren't Enough to Make the Stock a Buy Moderna's revenue came in better than expected last quarter, and the company raised its guidance. Nearly all of its revenue comes from COVID-related products.
View source ↗ - Newszacks.com·13d ago·Neutral
Can Moderna's First Cancer Therapy Win FDA Approval in 2027? MRNA targets a year-end 2026 FDA filing for its personalized cancer therapy, intismeran, potentially paving the way for a regulatory decision in 2027.
View source ↗ - Newszacks.com·13d ago·Positive
Moderna Q3 Earnings Call Highlights Raised Outlook and Oncology MRNA raises its 2026 revenue growth outlook after strong Q3 results, lower costs and respiratory vaccine gains, while advancing its oncology pipeline.
View source ↗ - Newsfool.com·13d ago·Neutral
BioNTech vs. Moderna: The COVID Vaccine Giants Are Entering a New Era. BioNTech and Moderna are working to reduce their dependence on COVID-19 vaccines through expanding pipelines in cancer treatment and other diseases. Moderna's latest quarterly results showed improving financial performance, alongside promising Phase 3 data for its personalized cancer vaccine.
View source ↗ - News (RSS)fool·13d ago·Negative
Moderna: 3 Key Takeaways for Long-Term Investors Its proprietary software is built into the cancer drug itself, creating a front-end design moat that rivals may struggle to replicate.
View source ↗ - Newsfool.com·14d ago·Neutral
Moderna: 3 Key Takeaways for Long-Term Investors Moderna raised full-year 2026 revenue growth guidance to 15% to 25%. Intismeran reduced the risk of melanoma recurrence or death by 42% in Phase 3.
View source ↗ - News (RSS)seekingalpha·14d ago·Neutral
Notable healthcare headlines for the week: Moderna, Pfizer, and CVS Health in focus
View source ↗ - 4chan /biz/biz·16d ago·Positive
>>62870292 +3.85% A little disappointed, it would have ended lower but Gold and Silver have been pumping for a week straight now. I expected more from TTWO today, but Moderna loves me at least.
View source ↗ - 4chan /biz/biz·16d ago·Neutral
>Moderna finally made positive $0.34 :OOOOOOO!!! Time to dump everything and buy.
View source ↗ - 4chan /biz/biz·16d ago·Neutral
>>62869999 What's so good about Moderna? People keep getting tricked into thinking they cured cancer, so it crabs a lot on the epiphany exits. They don't even have positive PE, but we beat the s*** out of NAND/DRAM.
View source ↗ - 4chan /biz/biz·16d ago·Neutral
>Elon couldve purchased Moderna 5 times over with the money he spent on the election
View source ↗ - 4chan /biz/biz·16d ago·Negative
I done shorted MRNA
View source ↗ - Newszacks.com·16d ago·Neutral
Moderna (MRNA) Stock Hits 52-Week Highs After Q3 Earnings: Buy, Hold, or Sell? Moderna stock has surged as much as 10% in Friday's trading session, reaching a fresh 52-week high after delivering much stronger-than-expected Q3 results.
View source ↗ - Newsseekingalpha.com·16d ago·Positive
Moderna, Inc. (MRNA) Q3 2026 Earnings Call Transcript Moderna, Inc. ( MRNA ) Q3 2026 Earnings Call November 6, 2026 8:00 AM EST Company Participants Lavina Talukdar - Senior VP & Head of Investor Relations Stéphane Bancel - CEO & Director James Mock - Chief Financial Officer Stephen Hoge - President David Berman - Chief Development Officer Conference Call Participants Salveen Richter - Goldman Sachs Group, Inc., Research Division Terence Flynn - Morgan Stanley, Research Division Eliana Merle - B…
View source ↗ - News (RSS)marketwatch·16d ago·Neutral
Moderna raises its revenue outlook — but all eyes are on what happens next with its cancer vaccine The company lifted its revenue outlook for the year, saying it expects revenue to grow as much as 25% in 2026.
View source ↗ - Newszacks.com·16d ago·Positive
MRNA Q3 Earnings Beat on COVID Sales, Raises '26 Outlook, Stock Rises Moderna's Q3 earnings beat estimates on strong COVID-19 vaccine sales, returning to profitability and boosting its 2026 revenue growth outlook.
View source ↗ - News (RSS)zerohedge·16d ago·Neutral
…yft (LYFT) falls 7% after the ride-hailing company gave a current quarter ride bookings and earnings forecast that came in largely in line with expectations.Moderna (MRNA) rises 3% after the vaccinemaker boosted its revenue growth guidance for the full year.Monster Beverage (MNST) slides 6% as the energy drink distributor reported a miss on third-quarter gross margin.Natera (NTRA) sinks 14% after the cancer test maker said CEO Steve Chapman was stepping down effectively immediately and succeeded…
View source ↗ - News (RSS)ft·16d ago·Positive
Moderna swings to profit as momentum for cancer vaccine builds Biotech company remains strongest performer in S&P 500 over past year
View source ↗ - Newsfool.com·16d ago·Positive
Moderna Turns a Profit as R&D Spending Falls: Rapid Earnings Reaction Revenue jumped 29% on international COVID vaccine sales tied to long-term government deals. Moderna raised its 2026 revenue growth outlook to 15% to 25%.
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
What Moderna (MRNA) Said on Its Q3 Earnings Call Moderna NASDAQ: MRNA raised its 2026 revenue growth outlook after reporting higher third-quarter sales and a return to quarterly profitability, as demand for its COVID-19 vaccines and international partnerships supported results.
View source ↗ - News247wallst.com·16d ago·Neutral
Moderna Climbs 5% as Surprise Profit and Raised Outlook Beat Forecasts; Pfizer Dips, BioNTech Edges Higher A quarter that produced a surprise profit and a bigger 2026 forecast is sending Moderna (NASDAQ:MRNA | MRNA Price Prediction) higher again. Moderna stock is at $254.07 in morning trading, up 5%.
View source ↗ - Newsfool.com·16d ago·Negative
Moderna Just Gave Investors Yet Another Thing to Cheer About Moderna earned a surprise profit in the third quarter, while analysts expected a loss of more than $1 per share. Management raised its full-year revenue growth outlook to 15% to 25% and cut its R&D budget.
View source ↗ - Newszacks.com·16d ago·Neutral
Moderna (MRNA) Q3 Earnings and Revenues Top Estimates Moderna (MRNA) came out with quarterly earnings of $0.38 per share, beating the Zacks Consensus Estimate of a loss of $1.1 per share. This compares to a loss of $0.51 per share a year ago.
View source ↗ - Newsbarrons.com·16d ago·Neutral
Moderna Stock Is Up 700% on Cancer Vaccine Hype. Earnings Reveal That Covid Still Counts. Moderna posts higher-than-expected revenue as results get a lift from international Covid vaccine demand.
View source ↗ - Newswsj.com·16d ago·Negative
Moderna Lifts Full-Year Outlook, Swings to Quarterly Profit The biopharmaceutical company said Friday it now expects total revenue growth of 15% to 25% for the year, compared with a previous outlook for up to 10% growth.
View source ↗ - Newsmarketwatch.com·16d ago·Neutral
Moderna's stock jumps after biotech raises sales outlook The company lifted its revenue outlook for the year, saying it now expects revenue to grow as much as 25% in 2026.
View source ↗ - Newsreuters.com·16d ago·Positive
Moderna lifts annual revenue forecast on strong COVID vaccine demand overseas Nov 6 (Reuters) - Moderna (MRNA.
View source ↗ - Newscnbc.com·16d ago·Neutral
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction Moderna smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%.
View source ↗ - Newsbenzinga.com·16d ago·Neutral
Moderna Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts Moderna, Inc. (NASDAQ:MRNA) will release earnings for its third quarter before the opening bell on Friday, Nov. 6.
View source ↗ - 4chan /biz/biz·16d ago·Negative
HOLY F*** I JUST REMEMBERED MRNA IT'S SUCH AN EASY SHORT DO IT
View source ↗ - 4chan /biz/biz·17d ago·Positive
>>62859008 god d*** that's grim I look back at MRNA if I full ported after the first giga pump I'd be a millionaire by now grim times
View source ↗ - News247wallst.com·17d ago·Neutral
Moderna, Humana and Elanco Earnings Previews: What Investors Should Watch One stock has soared more than sevenfold this year, another just lost a quarter of its value on leaked data, and a third carries the fate of millions of retirees. Friday's earnings could test each rally in very different ways.
View source ↗ - News (RSS)seekingalpha·17d ago·Neutral
Moderna Earnings Preview: The Melanoma Breakthrough Is Real, But $221 Is Way Too Much
View source ↗ - Newsseekingalpha.com·17d ago·Neutral
…$221 Is Way Too Much Moderna is rated Strong Sell at $220.83, with a working valuation of ~$60/share, implying 73% downside despite promising melanoma trial results. MRNA's Phase 3 melanoma data with intismeran and Keytruda shows a 42% relative reduction in relapse or death, but commercial and manufacturing hurdles remain. Pipeline optimism is reflected in valuation, but current revenues, persistent cash burn, and limited near-term product launches create a wide gap to the current equity value.
View source ↗ - 4chan /biz/biz·18d ago·Negative
Wait... Why did Moderna pump? They didn't cure cancer. They should be dumping like Ino.
View source ↗ - 4chan /biz/biz·18d ago·Positive
Look at Moderna that thing is ripping again. It doesnt f****** care it just goes and goes. Who knew curing cancer could be ao lucrative.
View source ↗ - News247wallst.com·19d ago·Neutral
Moderna Climbs 5% Ahead of Earnings, Pfizer Eases Despite Raised Outlook, Merck Slides 2% Despite New Phase 3 Trial Three of the biggest names in pharma and vaccines are trading against their own headlines. Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock is at $231.
View source ↗ - Newsfool.com·19d ago·Negative
Could Investing in Moderna's Stock Double Your Money? Intismeran is a promising cancer vaccine that has been highly effective when paired with Keytruda. Moderna is working with Merck on evaluating the vaccine for various types of cancers.
View source ↗ - Newsdefenseworld.net·19d ago·Negative
Moderna, Inc. $MRNA Stock Sold by Bank Julius Baer & Co. Ltd Zurich Bank Julius Baer and Co. Ltd Zurich reduced its stake in shares of Moderna, Inc. (NASDAQ: MRNA) by 35.0% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 61,075 shares of the company's stock after selling 32,845 shares during the quarter. Bank
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
…omorrow, and ARM, Qualcomm, McDonald’s, Novo Nordisk and Uber on Wednesday. Thursday’s slate includes Toyota, Sony, Deutsche Telekom, Rheinmetall and Nintendo, while Moderna and Mitsubishi Heavy Industries are among those reporting on Friday.Courtesy of DB, here is a day-by-day calendar of eventsMonday November 2Data: US October ISM index, September construction spending, China October RatingDog manufacturing PMI, Germany September retail sales, Italy October new car registrations, budget balanc…
View source ↗ - Newszacks.com·20d ago·Neutral
Buy Moderna Stock Before Q3 Earnings? Here's What to Know Moderna MRNA is scheduled to report third-quarter 2026 earnings on Nov. 6, before the opening bell. The Zacks Consensus Estimate for sales is pinned at $888.8 million, while that for earnings is pegged at a loss of $1.37 per share.
View source ↗ - News (RSS)zerohedge·20d ago·Neutral
…omorrow, and ARM, Qualcomm, McDonald's, Novo Nordisk and Uber on Wednesday. Thursday's slate includes Toyota, Sony, Deutsche Telekom, Rheinmetall and Nintendo, while Moderna and Mitsubishi Heavy Industries are among those reporting on Friday.Over the weekend, China's official PMIs delivered a noticeably weaker-than-expected start to Q4. The manufacturing PMI fell to 49.3 in October from 50.1 in September, below the 50.0 consensus. The details were also soft, with the production index falling to …
View source ↗ - Newsfool.com·20d ago·Positive
If Moderna's CEO Is Right, the Stock's Rally Could Just Be Getting Started Cancer vaccine intismeran has been highly effective in clinical trials when paired with Merck's Keytruda. In a recent trial, the combination reduced the risk of death or recurrence for melanoma patients by 42%.
View source ↗ - News (RSS)fool·20d ago·Positive
Stock Split Watch: Is Moderna Next? Moderna stock has skyrocketed this year.
View source ↗ - Newsfool.com·20d ago·Neutral
Stock Split Watch: Is Moderna Next? A stock split lowers the price of a stock, opening up the investing opportunity to a broader range of investors. Investors, excited about Moderna's personalized cancer vaccine candidate, have flocked to the stock this year.
View source ↗ - Newsyoutube.com·21d ago·Negative
Moderna, Merck eye FDA approval for promising cancer vaccine Moderna co-founder and board chairman Noubar Afeyan discusses the biotech company's melanoma vaccine trial results and efforts to secure FDA approval on 'The Claman Countdown.' #fox #foxbusiness #media #breakingnews #us #usa #new #news #breaking #theclamancountdown #moderna #merck #nubarafeyan #afeyan #cancer #cancervaccine #melanoma #cancerresearch #cancertreatment #vaccines #biotech #biotechnology #healthcare #healthnews #medicalrese…
View source ↗ - 4chan /biz/biz·23d ago·Positive
>>62836339 >AAPL beats >dumps 20% >AMD beats >dumps 20% >MCD pumps 30% in flight to safety >AMC pumps 30% because its funny >QCOM pumps 20% because its in SCHD and boomers are buying it by accident >CELH pumps 20% because its funny >MRNA dumps 60% on news that its cancer cure doesn't cure cancer cant wait
View source ↗ - Newszacks.com·23d ago·Neutral
Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline Moderna (MRNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - 4chan /biz/biz·24d ago·Neutral
MRNA just doesnt care. Its going back up again.
View source ↗ - Newszacks.com·24d ago·Neutral
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know Moderna (MRNA) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
View source ↗ - Newsfool.com·24d ago·Neutral
Will Moderna Soar on Nov. 6? Investors are excited about Moderna's personalized cancer vaccine candidate, which recently delivered positive clinical trial data. The stock surged after data was released in August but has given up some gains in recent days.
View source ↗ - 4chan /biz/biz·24d ago·Negative
>>62828934 Personally the moment I saw that giant red dildo I sold 100 shares of MRNA and bought 80 shares of GOOG. This is a better opportunity than curing cancer.
View source ↗ - News (RSS)thestreet·25d ago·Neutral
Breakthrough cancer vaccine catches Wall Street's attention Moderna and Merck's trial results in melanoma thrilled oncologists. Shareholders, however, felt differently.
View source ↗ - Newswsj.com·25d ago·Neutral
Moderna's CEO told The Wall Street Journal that his cancer vaccine's data will get better with time, and that no one can easily copy the company's work Stéphane Bancel defended his melanoma data and argued that rivals can't easily copy the technology.
View source ↗ - News247wallst.com·25d ago·Negative
Moderna Jumps 4% Despite William Blair Downgrade on Valuation; Novavax and BioNTech Edge Higher Shrugging off a valuation downgrade, Moderna (NASDAQ:MRNA | MRNA Price Prediction) is climbing as investors weigh strong cancer vaccine data against a share price that already reflects big expectations. Moderna stock stands at $217, up 4% this morning.
View source ↗ - Newsfool.com·25d ago·Neutral
Axsome Therapeutics vs. Moderna: Consistent Revenue Growth or Sharp Volatility Axsome Therapeutics (AXSM -1.29%) primarily discovers, develops, and exclusively commercializes innovative medical treatments targeting numerous central nervous system disorders domestically.
View source ↗ - 4chan /biz/biz·26d ago·Negative
>>62823295 Moderna keeps wanting to dump early market and then goes back up to at least even mid day. Does this mean something? I am pretty dumb.
View source ↗ - 4chan /biz/biz·26d ago·Neutral
>Moderna
View source ↗ - News (RSS)zerohedge·26d ago·Neutral
…eed to acquire it in a stock-and-cash deal with total enterprise value of ~$2.6b, paying $10.88 per fully diluted MFIC share. Ares Capital (ARCC) falls 1.9%.Moderna (MRNA) falls 3.2% after William Blair downgraded the drugmaker to market perform from outperform, citing valuation concerns, following a run-up in the stock.UPS (UPS) gains 2% after the courier raised its financial guidance for the year, suggesting it expects to benefit from high prices and resilient demand through the holiday season…
View source ↗ - 4chan /biz/biz·26d ago·Neutral
>>62822304 Just various Health stocks i followed. They all seem to be doing much better not just Moderna.
View source ↗ - 4chan /biz/biz·26d ago·Positive
>>62822281 spacex is crazy overvalued though. So is anthropic. You'll have bullish claims of revenue growth that will never match up. >>62822282 you mean like -30% in a day MRNA? That s*** is quite literally more volatile than any tech stock. >>62822284 based, old 4chan was the best, if only silver wasn't d****** as an investment. >>62822287 reddit
View source ↗ - Newsmarketbeat.com·26d ago·Negative
Merck and Moderna's Cancer Vaccine Worked—Who Gets Paid? Merck & Co. NYSE: MRK and Moderna NASDAQ: MRNA just cleared a bar no cancer vaccine had cleared before. Their personalized melanoma vaccine succeeded in a Phase 3 trial.
View source ↗ - News (RSS)seekingalpha·26d ago·Neutral
Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy - Slideshow
View source ↗ - Newsinvestopedia.com·27d ago·Positive
Moderna's Rally May Have Run Out of Steam. Here's What to Watch Next Moderna's stock has taken a big hit that could signal the end of this year's cancer vaccine-driven rally. It may not be too late to play the forces behind its rise.
View source ↗ - 4chan /biz/biz·27d ago·Neutral
>Moderna
View source ↗ - News (RSS)zerohedge·27d ago·Neutral
…ey upgraded the defense company to overweight from equal-weight, writing that a recent deal for F-35 fighter jets “takes significant risk out of the stock.” Moderna (MRNA) slumps 8.2%, set to extend their decline for a third session, after the drugmaker gave results from a trial of its experimental vaccine used in the treatment of pancreatic cancer. Nutanix Inc. shares (NTNX) are up 5.3% after Guggenheim Securities started coverage on the infrastructure software company with a buy rating and $10…
View source ↗ - 4chan /biz/biz·27d ago·Neutral
What's the floor on Moderna
View source ↗ - Newsmarketwatch.com·27d ago·Negative
The excitement around Moderna's cancer vaccine is cooling. Here's why. Investors had “incredibly high” expectations around the Phase 3 data for the drugmaker's experimental cancer treatment.
View source ↗ - News247wallst.com·27d ago·Negative
Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds Steady A closely tracked personalized melanoma vaccine met its main goal. Its effect on distant spread came in far smaller than an earlier study suggested in a late-stage trial.
View source ↗ - Newsbenzinga.com·27d ago·Negative
Moderna Stock Saga: Leaked Data, a Panicked Influencer and Perfect Timing Moderna Inc. (NASDAQ:MRNA) investors spent months treating the company's cancer vaccine as a potential cure. Last week, leaked trial data delivered a reality check.
View source ↗ - 4chan /biz/biz·27d ago·Neutral
MU and MRNA are going to gap up to $1500 and $300 respectively.
View source ↗ - News (RSS)zerohedge·28d ago·Positive
…ch has sought billions more for next-pandemic vaccines while the WHO and World Bank deploy large sums across dozens of nations. CEPI has directed tens of millions to Moderna for mRNA platforms, including work on an Ebola jab using the same technology as the COVID product. Gates has recently separately predicted that AI combined with ill-intent actors could drive events causing a billion deaths, describing AI as an evolutionary event more dangerous than previous technologies, and has warned of gr…
View source ↗ - News (RSS)decrypt·28d ago·Neutral
Wells Fargo, Cisco, Intuit Among 6 More Companies Objecting to Tokenized Stocks Twenty-two companies have now objected to having their shares traded on the planned OKX-ICE tokenized stock venue, after Wells Fargo, Cisco, Marvell, Arm, Moderna. and Intuit joined the list.
View source ↗ - News (Marketaux)gurufocus.com·28d ago·Neutral
Moderna (MRNA) Shares Plunge Over 17% After Leak of Cancer Vaccine Data On October 25, 2026, Moderna <e[+224 characters]
View source ↗ - 4chan /biz/biz·28d ago·Negative
Anything interesting i should know about that happened last week or is gonna happen on this one? What are you looking for/What surprised you? Mine from last week was the Moderna leak crashing the stock 25%.
View source ↗ - Newsseekingalpha.com·29d ago·Positive
Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript
View source ↗ - News (RSS)seekingalpha·29d ago·Neutral
Moderna: Why Positive Phase 3 Results Weren't Enough
View source ↗ - Newsmarketbeat.com·29d ago·Positive
Moderna Melanoma Therapy Cuts Recurrence Risk 42% in Phase 3 Trial Moderna NASDAQ: MRNA presented Phase 3 results for intismeran, its individualized neoantigen therapy, in combination with Merck's pembrolizumab for patients with resected high-risk melanoma. The INTerpath-001 trial met its primary endpoint of relapse-free survival and a key secondary endpoint of distant metastasis-free survival, according to lead investigator Georgina Long of Melanoma Institute Australia.
View source ↗ - News (RSS)barrons·29d ago·Negative
Moderna Investors Should Brace for More Whiplash Even after its latest sharp fall, the drugmaker’s stock price assumes wild successes.
View source ↗ - Newsfool.com·29d ago·Neutral
Breakfast News: A Conversation With Moderna's CEO This August, Moderna (MRNA -1.25%) and Merck (MRK -1.34%) reported that their personalized cancer vaccine, intismeran autogene, cut the risk of melanoma recurrence after surgery when added to Keytruda. The result came from a phase 3 trial, the large final-stage study regulators lean on for approval.
View source ↗
Earnings
Fri, Feb 12(in 3 months)
Consensus estimate $-2.07 per share
Typical surprise +23.6% (median, so one quarter with a near-zero estimate can't distort it)
- Fri, Nov 6$0.38 vs $-1.10beat
- Fri, Jul 31$-1.97 vs $-2.03beat
- Fri, May 1$-3.40 vs $-4.45beat
- Fri, Feb 13$-2.11 vs $-2.54beat
- Thu, Nov 6$-0.51 vs $-1.87beat
- Fri, Aug 1$-2.13 vs $-2.99beat
Estimates and results for MRNA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Earnings Call — 2026Q2
Management and analyst remarks, with per-speaker sentiment.
- Lavina TalukdarHead of Investor Relations+0.10
Thank you, Kevin. Good morning, everyone, and thank you for joining us on today's call to discuss Moderna's second quarter 2026 financial results and business update. You can access the press release issued this morning as well as the slides that we'll be reviewing by going to the Investors section of our website. On today's call are Stéphane Bancel, our Chief Executive Officer; Stephen Hoge, our …
- Stéphane BancelChief Executive Officer+0.80
Thank you, Lavina. Good morning or good afternoon, everyone. Thank you for joining us. After my review of the second quarter, Jamey will present our financial results and outlook, followed by Stephen with recent business updates. Then David will review our clinical progress in oncology and rare diseases. And then I will close by discussing our key value drivers. As you know, the second quarter is …
- Jamey MockChief Financial Officer+0.20
Thanks, Stéphane, and hello, everyone. Today, I'll start with our second quarter financial results and then review our updated financial framework for 2026. Let me start with our commercial performance. For the second quarter, total revenue was $145 million, above the guidance range we provided on the first quarter call. Our geographic mix for the quarter was 60% U.S. and 40% international. For th…
- Stephen HogePresident+0.60
Thank you, Jamey, and good morning or good afternoon, everyone. Today, I'll take you through our recent business updates. Slide 13 outlines our multiyear revenue growth strategy, anchored in geographic expansion and portfolio expansion from the continued advancement of our product pipeline. For 2026, we continue to expect revenue growth of up to 10%, driven by our long-term strategic partnerships …
- David BermanChief Development Officer+0.70
Thank you, Stephen. Before I begin the review of our oncology and rare disease pipeline, I want to take a moment to say how excited I am to be here. Before joining Moderna, I followed the company's oncology portfolio and Intismeran in particular, very closely. The strength and potential of the pipeline were an important part of what attracted me to the Chief Development Officer role. Since joining…
- Stéphane BancelChief Executive Officer+0.80
Thank you, David, Stephen and Jamey. Looking at the second half of the year, on the commercial and financial side, we remain on track for up to 10% revenue growth this year and also remain committed to improving our operational efficiency and achieving our new lowered cash cost guidance of approximately $4 billion. We also expect to build on last year's success mNEXSPIKE launch and to continue exp…
- Salveen RichterAnalyst (Goldman Sachs)+0.00
Two questions for me. One is in the case that the Phase III Intismeran melanoma study passes the first interim and progresses to a second and/or final analysis, how should we interpret that in the context of powering an event accrual? And how detailed will your disclosure be? And the second question for me is if the trial is indeed positive here, how do we think about read-through to other tumor t…
- David BermanChief Development Officer+0.20
Thank you very much. There are a lot of questions. Regarding the Phase III, to answer your first question, if the Phase III INT study in melanoma continues, it continues. We haven't disclosed the statistical powering or the thresholds for early interim efficacy, so I won't address that further. As for a press release, I think it's too early; let's see the data and then we'll decide the exact wordi…
Excerpts from MRNA's 2026Q2earnings call, via Alpha Vantage. Shown in part for commentary; refer to the company's own filings and investor relations site for the full call.
Insider trading
Open-market buys and sells by MRNA officers and directors.
- Bought
- —
- Sold
- $85.8m
0 trades
18 trades
- Hoge Stephensold
- Hoge Stephensold
- Hoge Stephensold
- Hoge Stephensold
- Hoge Stephensold
- Hoge Stephensold
- Hoge Stephensold
- Hoge Stephensold
82 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Gilbert Cisneroshouse · CA31 · disclosed Nov 10, 2026 (21d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Nov 9, 2026 (27d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (28d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 9, 2026 (35d later)Buy$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Oct 8, 2026 (14d later)Sell$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Sep 10, 2026 (22d later)Sell$1,001 - $15,000
- Maria Elvira Salazarhouse · FL27 · disclosed Sep 10, 2026 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 10, 2026 (12d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Sep 12, 2025 (17d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Aug 8, 2025 (14d later)Buy$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed May 8, 2025 (30d later)Sell$1,001 - $15,000
- Robert P. Bresnahanhouse · PA08 · disclosed Mar 28, 2025 (31d later)Buy$1,001 - $15,000
- Julie Johnsonhouse · TX32 · disclosed Feb 12, 2025 (28d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Oct 8, 2024 (29d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Apr 5, 2024 (16d later)Sell$1,001 - $15,000
- Josh Gottheimerhouse · NJ05 · disclosed Mar 7, 2024 (35d later)Sell$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Mar 6, 2024 (22d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Feb 5, 2024 (26d later)Buy$1,001 - $15,000
- Ro Khannahouse · CA17 · disclosed Dec 6, 2023 (33d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
